While a lot of drug repurposing research was made focusing on anti-viral drug treatments and combinations [14,15,16,17,18,19,20,21,22], here, we focused on drugs approved to treat ALK-positive cancers (alectinib, ceritinib, crizotinib, brigatinib, entrectinib, lorlatinib [10]) to target ALK-negative but LTK-positive mature B cells. Here, ALK is linked to cancer.